[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
Article
August 1969

Safety Testing of Rubella Virus Vaccine (Cendehill Strain): Preparation in Primary Rabbit Kidney Cells

Author Affiliations

Genval, Belgium; Miami, Fla; Genval, Belgium; Louvain, Belgium; Philadelphia
From the Biologics Department, Recherche and Industrie Therapeutiques, Genval, Belgium (Drs. Huygelen and Zygraich, and Mr. Peetermans and Colinet); the University of Miami School of Medicine and Variety Children's Research Foundation, Miami, Fla (Dr. Sigel); Rega Institute, University of Louvain, Belgium (Mr. Leyten); and the Research and Development Division, Smith, Kline & French Laboratories, Philadelphia (Mr. Raupp and Pinto, and Drs. Garg, Boyle, and Haff).

Am J Dis Child. 1969;118(2):362-366. doi:10.1001/archpedi.1969.02100040364035
Abstract

THE CENDEHILL strain of rubella virus has been attenuated by serial passages in primary rabbit kidney (PRK) cells; details of its passage history and biological properties have been published.1-3

After small scale clinical trials with various passage levels, the 51st passage was chosen for further evaluation. In subsequent trials, in larger groups of children and adults, this passage level appeared to possess all the properties desired for a live rubella virus vaccine, and so a large seed lot was prepared from it, tested for safety, and is being used to produce experimental batches of vaccine. The resulting vaccine, which has been evaluated in large scale clinical trials, corresponds to the 53rd passage level of the virus in PRK cells.

The production of Cendehill rubella vaccine includes the same steps as the production of live measles vaccine, namely: preparation of tissue cultures, inoculation with seed virus, harvesting, pooling, clarification, and

×